Press release
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical
About this update from Keros Therapeutics, Inc.
[{"type":"text","content":"LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that the Company will be featured on Behind the Mystery, a recurring series highlighting rare diseases, to raise awareness of the devastating condition, fibrodysplasia ossificans progressiva (“FOP”).\n The segment, sponsored by Keros, will feature Nancy Sando, patient and one of the founding members and board member of the International FOP Association (“IFOPA”), along with Dr. Richard Keen, treating physician and researcher. The segment will cover scientific and medical aspects of this rare disorder and the daily challenges faced by patients with this debilitating disease through the life story of one patient living with FOP and from those providing medical care. “Keros is honored to have the opportunity to bring awareness of FOP to a wider audience. The Company was founded with a mission to develop treatments for rare diseases and developing a therapy for patients with FOP underscores the importance of our mission,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. “We sincerely thank both Nancy and Professor Keen for participating in the segment and bringing a voice to the challenges that all patients with FOP face daily.” The segment is expected to air on The Balancing Act on Lifetime® Thursday, August 13, 2020 (at 7:30 AM, ET/PT) and again on Tuesday, September 1, 2020 (at 7:30 AM ET/PT), after which it will be shown in syndication. Keros collaborated with the IFOPA on the production of the segment. “As a voice of the FOP community, IFOPA has a mission to educate and raise awareness of FOP, and a segment such as this with a wide audience is invaluable in doing that,” said Adam Sherman, Research Development and Partnerships Director of IFOPA. “We were pleased to have this opportunity to work with Keros and are grateful for the participation of one of our early members, Nancy Sando, along with a key member of the clinical community.” For the past eight years, Behind the Mystery has spotlighted undiagnosed, misdiagnosed and complex medical disor...